Silver Book Fact

Supplementation with lutein increases macular pigment optical density by 27%; which is correlated with benefits in visual function.

Weigert G, Kay S, Pemp B, Sacu S, et al. Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients with Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. October 2011; 52(11): 8174-8. http://www.iovs.org/content/52/11/8174.abstract

Reference

Title
Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients with Age-Related Macular Degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
October 2011
Authors
Weigert G, Kay S, Pemp B, Sacu S, et al.
Volume & Issue
Volume 52, Issue 11
Pages
8174-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The prevalence of age-related macular degeneration (AMD) in the 40 and older population has decreased from an estimated 9.4% from 1988 to 1994, to 6.5% for 2005 to 2008.  
  • Detection and treatment of proliferative diabetic eye disease and clincally significant macular edema with laser therapy can reduce severe vision loss progression by 50% to 60%  
  • Multifoca electroretinogram (mFERG) measures show abnormal function of the retina early in–and even prior to–diabetic retinopathy onset and could enhance monitoring of the early stages of disease progression in individuals.  
  • High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…